Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Southern Europe

Southern Europe

The Neoplasm Treatment market in Southern Europe is projected to achieve a revenue of US$15.29bn by 2024.
The market is expected to exhibit an annual growth rate (CAGR 2024-2029) of 2.94%, leading to a market volume of US$17.67bn by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$90.56bn in 2024.
In Southern Europe, Spain has seen a surge in the adoption of innovative neoplasm treatment methods, positioning itself as a leading player in the region.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.